Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis

Trial Profile

A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Reproxalap (Primary) ; Corticosteroids; Prednisolone acetate
  • Indications Anterior uveitis
  • Focus Therapeutic Use
  • Sponsors Aldeyra Therapeutics
  • Most Recent Events

    • 05 Nov 2020 According to an Aldeyra Therapeutics media release, the peer-reviewed Journal of Ocular Pharmacology and Therapeutics published the positive results of a randomized, corticosteroid-controlled Phase 2 clinical trial of reproxalap in patients with noninfectious anterior uveitis
    • 25 Oct 2017 According to an Aldeyra Therapeutics media release, data from this trial will presented at the American Uveitis Society Fall Meeting held in conjunction with the American Academy of Ophthalmology 2017 Annual Meeting.
    • 17 May 2017 According to an Aldeyra Therapeutics media release, data was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top